Condition: Biliary Tract Cancer · Sponsor: Taiho Pharmaceutical Co., Ltd.
To compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer
This description comes directly from the study's public registry record.
Kotaro Suto · +81-3-3294-4527 · th-FOENIX-BTC-Clin.Dev@taiho.co.jp
Always discuss trial participation with your own doctor first.
| Research Site | Brisbane, Australia | Not Yet Recruiting |
| Research Site | Melbourne, Australia | Not Yet Recruiting |
| Research Site | Perth, Australia | Not Yet Recruiting |
| Research Site | Sydney, Australia | Not Yet Recruiting |
| Research Site | Aichi, Japan | Not Yet Recruiting |
| National Hospital Organization Kyushu Cancer Center | Fukuoka, Japan | Recruiting |
| Research Site | Fukuoka, Japan | Not Yet Recruiting |
| Research Site | Hokkaido, Japan | Not Yet Recruiting |
| Kanagawa Cancer Center | Kanagawa, Japan | Not Yet Recruiting |
| Research Site | Miyagi, Japan | Not Yet Recruiting |
| Research Site | Osaka, Japan | Not Yet Recruiting |
| Research Site | Tokyo, Japan | Not Yet Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07710885